Enrich Therapeutics Recieved SBIR Phase 1 Grant

Enrich Therapeutics has been awarded a Small Business Innovation Research(SBIR) phase 1 grant from National Institute of Health(NIH) in June 2019. The award will support our expedited development of disruptive single cell isolation platform as well as integrated novel applications.